Monopar Therapeutics (MNPR) Total Liabilities (2016 - 2020)

Monopar Therapeutics' Total Liabilities history spans 5 years, with the latest figure at $664468.0 for Q3 2020.

  • For Q3 2020, Total Liabilities rose 37.38% year-over-year to $664468.0; the TTM value through Sep 2020 reached $664468.0, up 37.38%, while the annual FY2019 figure was $724165.0, 81.24% up from the prior year.
  • Total Liabilities for Q3 2020 was $664468.0 at Monopar Therapeutics, up from $648148.0 in the prior quarter.
  • Across five years, Total Liabilities topped out at $724165.0 in Q4 2019 and bottomed at $64510.0 in Q4 2016.
  • The 5-year median for Total Liabilities is $443520.0 (2020), against an average of $439515.8.
  • The largest annual shift saw Total Liabilities soared 383.44% in 2017 before it decreased 23.53% in 2020.
  • A 5-year view of Total Liabilities shows it stood at $64510.0 in 2016, then skyrocketed by 383.44% to $311867.0 in 2017, then increased by 28.12% to $399551.0 in 2018, then surged by 81.24% to $724165.0 in 2019, then dropped by 8.24% to $664468.0 in 2020.
  • Per Business Quant, the three most recent readings for MNPR's Total Liabilities are $664468.0 (Q3 2020), $648148.0 (Q2 2020), and $443520.0 (Q1 2020).